There seems to be some debate over the value of beta-blockers in the treatment of hypertension, especially in elderly patients. [1] [2] [3] We report on a hypertensive woman where beta-blocker treatment was almost an essential requirement, to prevent concomitant paroxysmal atrial fibrillation.
A 70-year-old Caucasian lady first presented in 1984 with hypertension for which she was treated with propranolol (as Inderal LA 60 mg a day) and Moduretic 1 tablet (coamilozide 2.5/25 or amiloride 2.5 mg/hydrochlorthiazide 25 mg combined formulation). She had few symptoms apart from occasional palpitations, suggestive of extrasystoles. Past medical history included rheumatic fever at the age 21. Her blood pressure was 170/105 mm Hg and fundal examination showed grade 2 hypertensive changes. A 12-lead ECG showed sinus rhythm with a right bundle branch block and no LVH. Five years later she was changed from propranolol to atenolol 50 mg daily, which was subsequently increased to 100 mg a day. Nevertheless her blood pressure remained difficult to control and enalapril was eventually added to her regime but she developed a troublesome cough, so she was changed to Tenoretic 1 tablet (cotenidone 108/25 or atenolol 100 mg/chlorthalidone 25 mg) a day.
Her cholesterol was elevated at 6.8 mmol/l, triglyceride at 2.18 mmol/l and HDL-cholesterol 0.1 mmol/l. In view of the raised cholesterol and low HDL levels, it was decided that her betablocker-diuretic regime should be changed to lisinopril 10 mg daily. Nevertheless, she complained of headaches, diarrhoea and some Correspondence to: Dr GYH Lip. This letter was submitted to and considered via the USA office of this journal.
palpitations after stopping the beta-blocker. Her general practitioner therefore stopped the lisinopril and restarted Tenoretic. As her blood pressure again became difficult to control and as her potassium was found to be low at 2.9 mmol/L, her treatment was again changed to atenolol 100 mg alone, but this was subsequently stopped in April 1998 and candesartan 8 mg substituted in an attempt to control her blood pressure.
However, 24 h after stopping the atenolol she complained of fast palpitations with an erratic and irregular pulse requiring hospital admission. On presentation, her blood pressure was 170/90 mm Hg with a pulse rate of 130 bpm. ECG showed a broad complex tachycardia with heart rate of 130-150 per minute. A bolus of intravenous adenosine revealed underlying atrial fibrillation, which spontaneously reverted to sinus rhythm within 24 h after the candesartan was discontinued and atenolol restarted. Due to the atrial fibrillation and hypertension she was started on anticoagulation, particularly since she was intolerant of aspirin therapy. An echocardiogram showed a structurally normal heart with a normal sized left ventricle and left atrium, and normal left ventricular function. There was no evidence of significant mitral valve disease.
This case illustrates the problem of hypertension complicated by adrenergically mediated paroxysmal atrial fibrillation. The beta-blockers used to treat her hypertension also appeared to suppress the sympathetic drive to develop paroxysms of atrial fibrillation. Adrenergically-induced atrial fibrillation is less common than the vagal type, occurring usually during daytime, and often proceeded by exercise and emotional stress. 4 There is an association with cardiovascular disease and paroxysms are often preceeded by heart rate acceleration, and a mixed picture of atrial tachycardia/atrial fibrillation is seen. Beta-blockers and digoxin are usually the treatment of choice in adrenergic atrial fibrillation. By contrast, the vagal form is the more common type, and characterised by a predominance in men with the age of onset between 40 to 50 years, the absence of structural heart disease, occurrence at night or during rest, after eating, or with consumption of alcohol. Vagal atrial fibrillation is usually preceded by bradycardia and a mixed atrial flutter/fibrillation pattern is often seen. Importantly, both betablockers and digoxin may increase the frequency of vagal atrial fibrillation.
We suggest that our hypertensive patient may be one where beta-blockers should be continued indefinitely to treat both the hypertension and to surpress the (adrenergic) paroxysmal atrial fibrillation.
The differences between vagally-and adrenergically-induced atrial fibrillation 4 are often neglected and patients such as ours illustrate the need to be aware of the different management strategies for such patients. However, the possibility still arises that in elderly hypertensive patients, beta-blockers may lower the blood pressure and adequately treat concomitant disorders (for example, arrhythmias) but without providing an adequate primary cardioprotective effect. 
